Association of cystatin C with left ventricular structure and function : The Dallas Heart Study

Circulation: Heart Failure

Volumn 2, Issue 2, 2009, Pages 98-104

  Patel, Parag C ^a   Ayers, Colby R ^a   Murphy, Sabina A ^b   Peshock, Ronald ^a   Khera, Amit ^a   De Lemos, James A ^a   Balko, Jody A ^a   Gupta, Sachin ^a   Mammen, Pradeep P A ^a   Drazner, Mark H ^a   Markham, David W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Concentricity; Cystatin C; Dallas Heart Study; Hypertension; Left ventricular hypertrophy; Rrenal function

Indexed keywords

CREATININE; CYSTATIN C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEART DISEASES; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PHENOTYPE; SEX FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 67650624206     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.807271     Document Type: Article

References (38)

1. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001; 38:955-962.
2. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, Velazquez EJ, McMurray JJ, Pfeffer MA, Solomon SD. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J Am Coll Cardiol. 2007; 50:1238 -1245.
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296 -1305.
4. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004; 15:2195-2203.
5. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 1990; 38:167-184.
6. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001; 37:79-83.
7. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C-a new marker of glomerular filtration rate in children independent of age and height. Pediatrics. 1998; 101:875- 881.
8. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem. 1998; 44:1535-1539.
9. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol. 2006; 21:1223-1230.
10. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995; 47:312-318.
11. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000; 36:29 -34.
12. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis. 2006; 185:375-380.
13. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007; 28:1841-1847.
14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005; 51:321-327. (Pubitemid 40175801)
15. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Cardiac Fail. 2006; 12:601- 607.
16. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007; 115:173-179.
17. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, Siscovick D, Psaty BM, Sarnak MJ. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005; 45:268 -271.
18. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004; 93:1473-1480.
19. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999; 59:1- 8.
20. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 2005; 16:507-513. (Pubitemid 41725148)
21. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, Willett D, Victor RG. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension. 2005; 46:124 -129.
22. Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, Canham RM, Levine BD, Drazner MH. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation. 2006; 113: 1597-1604.
23. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005; 112: 2163-2168.
24. Kelly TL, Berger N, Richardson TL. DXA body composition: theory and practice. Appl Radiat Isot. 1998; 49:511-513.
25. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH, Grundy SM, McGuire DK. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation. 2006; 113:38-43.
26. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, Higaki J. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003; 26:895- 899.
27. Strevens H, Wide-Swensson D, Grubb A, Hansen A, Horn T, Ingemarsson I, Larsen S, Nyengaard JR, Torffvit O, Willner J, Olsen S. Serum cystatin C reflects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies. BJOG. 2003; 110:825- 830.
28. Olivieri O, Bassi A, Pizzolo F, Tinazzi E, Corrocher R. Cystatin C versus creatinine in renovascular disease. Clin Chem. 2002; 48:2256 -2259.
29. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007; 49:198 -207.
30. Mitsnefes M, Kimbal T, Kartal J, Kathman T, Mishra J, Devarajan P. Serum cystatin C and left ventricular diastolic dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2006; 21:1293-1298. (Pubitemid 44203456)
31. Afshinnia F, Spitalewitz S, Chou SY, Gunsburg DZ, Chadow HL. Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure. Am J Kidney Dis. 2007; 49:227-236.
32. Djousse L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J. 2008; 155:82- 86.
33. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaka T, Saka M, Kimata T, Noda A, Nagata K, Jin H, Shi GP, Iguchi A, Murohara T, Yokota M. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension. 2006; 48:979 -987.
34. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, Monnig G, Haverkamp W, Breithardt G, Schmahl W, Peters C, Reinheckel T. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA. 2002; 99:6234-6239.
35. Sam F, Siwik DA. Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure. Hypertension. 2006; 48:830-831.
36. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65:1416 -1421.
37. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant. 2007; 22:1087-1092. (Pubitemid 46523422)
38. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005; 118:1416.